Impax Laboratories Confirms Patent Challenge Relating to RENVELA(R), 2.4 g and ... - MarketWatch (press release) PDF Print
MarketWatch (press release)RENVELA(R) is indicated for the control of serum phosphorus in patients with Chronic Kidney Disease on dialysis. According to Wolters Kluwer Health,

... read more

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.